<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03140969</url>
  </required_header>
  <id_info>
    <org_study_id>PQ-110-001</org_study_id>
    <secondary_id>2017-000813-22</secondary_id>
    <nct_id>NCT03140969</nct_id>
  </id_info>
  <brief_title>Study to Evaluate QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A&gt;G Mutation (p.Cys998X) in the CEP290 Gene</brief_title>
  <official_title>An Open-label, Single Arm, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A&gt;G Mutation (p.Cys998X) in the CEP290 Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProQR Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProQR Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of QR-110 administered
      via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of QR-110 administered
      via intravitreal injection in subjects with LCA due to the CEP290 p.Cys998X mutation.
      Subjects will receive QR-110 in one eye every 3 months, for a maximum of 4 doses. Up to 3
      dose levels of QR-110 will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and severity of ocular adverse events in the treatment and contralateral eyes</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of non-ocular adverse events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ophthalmic examination findings</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in best-corrected visual acuity (BCVA)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in infrared imaging</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in optical coherence tomography (OCT) findings</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in safety parameters, including vital sign measurements, physical examination findings, ECG and laboratory parameters</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve 0 hour to infinity [AUC(0-∞)] of QR-110 in serum (if measurable)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve 0 hour to time of the last measurable concentration [AUC(0-t)] of QR-110 in serum</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax ) of QR-110 in serum</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum concentration (Cmin) of QR-110 in serum</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum concentration (Tmax ) of QR-110 in serum</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half life (T1/2) of QR-110 in serum (if measurable)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of QR-110 in serum (if measurable)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) of QR-110 in serum (if measurable)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in full-field stimulus test (FST)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pupillary light reflex (PLR)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Leber's Congenital Amaurosis</condition>
  <arm_group>
    <arm_group_label>QR-110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered every 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QR-110</intervention_name>
    <description>RNA antisense oligonucleotide for intravitreal injection</description>
    <arm_group_label>QR-110</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, ≥ 6 years of age at Screening with a clinical diagnosis of LCA and a
             molecular diagnosis of homozygosity or compound heterozygosity for the CEP290
             p.Cys998X mutation.

          -  Best-corrected visual acuity greater than or equal to light perception in both eyes
             and equal to or worse than LogMAR +1.0 (Snellen notation 20/200) in the worse eye and
             equal to or worse than LogMAR +0.7 (Snellen notation 20/100) in the contralateral eye.

          -  Detectable outer nuclear layer (ONL) in the area of the macula.

          -  An electroretinogram (ERG) result consistent with LCA.

          -  Clear ocular media and adequate pupillary dilation to permit good quality retinal
             imaging.

        Exclusion Criteria:

          -  Syndromic disease.

          -  Pregnant or breast-feeding female.

          -  Any clinically significant cardiac disease or defect.

          -  One or more coagulation parameters outside of the normal range.

          -  Any ocular disease or condition that could compromise treatment safety, visual acuity
             or interfere with assessment of efficacy and safety.

          -  Prior receipt of intraocular surgery or intravitreal injection within 3 months prior
             to study start or planned intraocular surgery or procedure during the course of the
             study.

          -  Use of any investigational drug or device within 90 days or 5 half-lives of Day 1,
             whichever is longer, or plans to participate in another study of a drug or device
             during the PQ-110-001 study period.

          -  Any prior receipt of genetic therapy for LCA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ProQR Study Director</last_name>
    <role>Study Director</role>
    <affiliation>ProQR Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Manager</last_name>
    <phone>+31 6 20 183 437</phone>
    <email>clinical@proqr.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephen R. Russell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arlene Drack, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scheie Eye Institute, University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Artur V. Cideciyan, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel G. Jacobson, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital and Ghent University</name>
      <address>
        <city>Ghent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bart P.R. Leroy, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie De Zaeytijd, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irina Balikova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2017</study_first_posted>
  <last_update_submitted>March 13, 2018</last_update_submitted>
  <last_update_submitted_qc>March 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CEP290</keyword>
  <keyword>p.Cys998X</keyword>
  <keyword>c.2991+1655A&gt;G</keyword>
  <keyword>RNA therapy</keyword>
  <keyword>Antisense oligonucleotide</keyword>
  <keyword>Leber's congenital amaurosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blindness</mesh_term>
    <mesh_term>Leber Congenital Amaurosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

